Endo to Buy U.S. Drugmaker Qualitest for $1.2 Billion

Endo Pharmaceuticals Holdings Inc. agreed to buy U.S. generic-drugmaker Qualitest Pharmaceuticals for about $1.2 billion from private-equity firm Apax Partners LLP. Endo’s shares rose to their highest value in three years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.